drugset / Trial / NCT00613028
Ph II Bev + Either Temozolomide/Etoposide for GBM Pts Who Have Failed Bev + Irinotecan
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Primary objective To estimate 6-month progression free survival probability of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan Secondary Objectives To evaluate safety \& tolerability of bev + either daily temozolomide/etoposide among pts w recurrent GBM who have progressed on bev + irinotecan To evaluate radiographic response, progression free survival \& overall survival of pts w recurrent GBM treated w bev + either daily temozolomide/etoposide following progression on bev + irinotecan
Timeline
- Start
- 2008-04
- Primary completion
- 2009-10
- Completion
- 2011-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Etoposide | Small molecule | 50 mg/m2 | — |
| Subject | Temozolomide | Small molecule | 50 mg/m2 | — |
| Background | Bevacizumab | Monoclonal antibody | 10 mg/kg | Intravenous |